Solutions
- Research Type
  - ETF Data & AnalyticsThe data and analytics you need to navigate the ETF universe.
  - ETF & Mutual Fund ResearchA forward focused, holistic approach to fund insights.
  - Forensic Accounting ResearchUnderstand implications of public company financial reporting.
  - Fundamental Equity ResearchGain a comprehensive view of global themes, industries, and companies.
  - Public Policy & Legal ResearchIdentify opportunity and risk driven by public policy and the courts.
  - Technical ResearchGiving you confidence to navigate any market cycle.
Who We Serve
- Client Type
  - Wealth ManagementFull-service Broker-Dealers, Online Broker-Dealers, Wealth Management Firms, Private Banks, RIAs
  - Institutional InvestorsHedge Funds, Asset Managers, Pension Funds, Sovereign Wealth Funds, Private Equity, Family Offices
  - Financial AdvisorsFinancial Advisors, Relationship Managers, Wealth Managers
  - Individual InvestorsSelf-directed individual investors
Insights
About
- About CFRA
Login

Solutions
- Research Type
  - ETF Data & AnalyticsThe data and analytics you need to navigate the ETF universe.
  - ETF & Mutual Fund ResearchA forward focused, holistic approach to fund insights.
  - Forensic Accounting ResearchUnderstand implications of public company financial reporting.
  - Fundamental Equity ResearchGain a comprehensive view of global themes, industries, and companies.
  - Public Policy & Legal ResearchIdentify opportunity and risk driven by public policy and the courts.
  - Technical ResearchGiving you confidence to navigate any market cycle.
Who We Serve
- Client Type
  - Wealth ManagementFull-service Broker-Dealers, Online Broker-Dealers, Wealth Management Firms, Private Banks, RIAs
  - Institutional InvestorsHedge Funds, Asset Managers, Pension Funds, Sovereign Wealth Funds, Private Equity, Family Offices
  - Financial AdvisorsFinancial Advisors, Relationship Managers, Wealth Managers
  - Individual InvestorsSelf-directed individual investors
Insights
About
- About CFRA
Login

Insights

Access our latest insights & resources

Filters

Sectors

Research Type

Content Type

Sector: Healthcare

Implications of the Medicare Price Negotiations Announcement for BMY and JNJ

Implications of the Medicare Price Negotiations Announcement for BMY and JNJ

Fundamental, Research

The Centers for Medicare & Medicaid Services (CMS) released a list...

August PDUFA Calendar

August PDUFA Calendar

Policy & Legal, Research

August will be a busy month for FDA approvals with unofficially 22 applications...

Shockwave (SWAV): No Higher Rates For Now

Shockwave (SWAV): No Higher Rates For Now

Policy & Legal, Research

In omitting any narrative discussion of Shockwave’s (SWAV) coronary lithotripsy device..

FDA Action on Aspartame Unlikely

FDA Action on Aspartame Unlikely

Policy & Legal, Research

Recent reports that the World Health Organization (WHO) will reclassify aspartame...

[CVS, CI, UNH, ELV, HUM]: PBM Policy Noise and Concerns

[CVS, CI, UNH, ELV, HUM]: PBM Policy Noise and Concerns

Policy & Legal, Research

The House Education and Workforce Committee markup of four healthcare bills and the reported...

European Health Care Equipment & Services: Receding Headwinds

European Health Care Equipment & Services: Receding Headwinds

Fundamental, Research

We see easing headwinds for the European Health Care Equipment & Services industry...

Revvity: Revitalized for Stronger Growth

Revvity: Revitalized for Stronger Growth

Fundamental, Research

Rebranded as Revvity, it aims at becoming a high growth, high margin firm...

Health Care REITs Poised for Healthy Returns

Health Care REITs Poised for Healthy Returns

Fundamental, Video

The aging US population and increasing healthcare expenditures...

[CVS, CI, UNH, ELV]: Entrenchment of PBM Overhang with More Bills Expected

[CVS, CI, UNH, ELV]: Entrenchment of PBM Overhang with More Bills Expected

Policy & Legal, Research

No relief for PBMs [CVS (CVS), Cigna (CI),...

May 2023 PDUFA Calendar

May 2023 PDUFA Calendar

Policy & Legal, Research

Delays in approvals due to disrupted work schedules at FDA because of the coronavirus...